Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nascent Biotech Inc NBIO

Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a... see more

Recent & Breaking News (OTCQB:NBIO)

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run

Accesswire 10 days ago

Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System

Accesswire March 19, 2024

Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

Accesswire February 6, 2024

Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued

Accesswire January 9, 2024

Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk

Accesswire December 19, 2023

Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier

Accesswire November 29, 2023

Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer

Accesswire August 22, 2023

Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting

Accesswire June 7, 2023

Nascent Biotech Regains Worldwide Rights for Pritumumab

Accesswire May 26, 2023

Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting

Accesswire May 9, 2023

Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval

Accesswire April 18, 2023

Nascent Announces the Completion of Its Phase1 Clinical Trials

Accesswire February 28, 2023

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

Accesswire January 25, 2023

Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial

Accesswire January 10, 2023

Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board

Accesswire December 20, 2022

Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394

Accesswire November 1, 2022

Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research

Accesswire October 4, 2022

Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Accesswire September 13, 2022

Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent

Accesswire July 19, 2022

Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Accesswire June 7, 2022